In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies

Journal of Pharmacological Sciences

Volumn 128, Issue 1, 2015, Pages 54-57

  Uchida, Saeko ^a   Mitani, Akiko ^a   Gunji, Emi ^a   Takahashi, Teisuke ^a   Yamamoto, Koji ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Binding kinetics; Inhibition model; Sodium glucose co transporter 2 inhibitor

Indexed keywords

GLUCOSE; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; SORBITOL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL LINE; COMPETITIVE BINDING ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; GLUCOSE TRANSPORT; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; CELL CULTURE; HALF LIFE TIME; HUMAN; KIDNEY PROXIMAL TUBULE; KINETICS; METABOLISM; TIME FACTOR;

BINDING SITES; BINDING, COMPETITIVE; CELLS, CULTURED; GLUCOSE; HALF-LIFE; HUMANS; KIDNEY TUBULES, PROXIMAL; KINETICS; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TIME FACTORS;

EID: 84930083149     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2015.04.001     Document Type: Article

References (12)

1. Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, and Y. Samukawa Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study Curr Med Res Opin 30 2014 1219 1230
2. N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta, and H. Kuki Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study Diabetes Obes Metab 15 2013 1136 1145
3. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
4. H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, and Y. Fukasawa (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J Med Chem 53 2010 3247 3261
5. K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, and E. Gunji TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity Br J Pharmacol 164 2011 181 191
6. T. Sasaki, Y. Seino, A. Fukatsu, S. Sakai, and Y. Samukawa Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial Adv Ther 31 2014 345 361
7. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, and D.E. Sharp Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 2012 83 90
8. +/glucose cotransporters J Pharmacol Exp Ther 324 2008 985 991
9. M. Suzuki, K. Honda, M. Fukazawa, K. Ozawa, H. Hagita, and T. Kawai Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice J Pharmacol Exp Ther 341 2012 692 701
10. C.S. Hummel, C. Lu, J. Liu, C. Ghezzi, B.A. Hirayama, and D.D. Loo Structural selectivity of human SGLT inhibitors Am J Physiol Cell Physiol 302 2012 C373 C382
11. +/D-glucose cotransporters SGLT1 and SGLT2 Am J Physiol Cell Physiol 300 2011 C14 C21
12. C. Ghezzi, B.A. Hirayama, E. Gorraitz, D.D. Loo, Y. Liang, and E.M. Wright SGLT2 inhibitors act from the extracellular surface of the cell membrane Physiol Rep 2 2014 e12058